Hematologic Malignancy Clinical Trials & Research at St. Joseph Health Medical Group

St. Joseph Health Medical Group is currently enrolling patients for the following hematologic malignancy clinical trials:

Myelofibrosis and Essential Thrombocythemia
Myelodysplastic Syndrome
Acute Myeloid Leukemia
Chronic Lymphocytic Leukemia
Lymphoma
Multiple Myeloma


Myelofibrosis and Essential Thrombocythemia

Prospective, Longitudinal, Non-Interventional Study of Disease Burden and Treatment of Patients With Low-Risk Myelofibrosis (Mf) or High-Risk Essential Thrombocythemia (Et) or Et Patients Receiving Et-Directed Therapy (MOST)

Treatment agent: N/A
PI: Jarrod Holmes, MD
Study Coordinator: Catherine Hollister // Catherine.Hollister@stjoe.org // (707) 521-3808
Resources and Links: clinicaltrials.gov NCT No: NCT02953704


Myelodysplastic Syndrome

A Phase 3 Randomized Double-Blind Placebo-Controlled Study Investigating the Efficacy and Safety of Roxadustat (FG-4592) for Treatment of Anemia in Patients with Lower Risk Myelodysplastic Syndrome (MDS) with Low Red Blood Cell (RBC) Transfusion Burden (LTB) (Fibrogen)

Treatment agent: Roxadustat
PI: Jarrod Holmes, MD
Study Coordinator: Study Coordinator: Tracy Foster // Tracy.Foster@stjoe.org // (707) 521-3836
Resources and Links: clinicaltrials.gov NCT No: NCT03263091


Acute Myeloid Leukemia

The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry (Connect MDS/AML)

Treatment agent: N/A
PI: Thomas Stanton, MD
Study Coordinator: Diego Martinez // Diego.Martinez@stjoe.org // (707) 521-3810
Resources and Links: clinicaltrials.gov NCT No: NCT01688011


Chronic Lymphocytic Leukemia

A Disease Registry for Patients with Chronic Lymphocytic Leukemia (InformCLL)

Treatment agent: N/A
PI: Wes Lee, MD
Study Coordinator: Diego Martinez // Diego.Martinez@stjoe.org // (707) 521-3810
Resources and Links: clinicaltrials.gov NCT No: NCT02582879

back to top


Lymphoma

Follicular Lymphoma
Marginal Zone Lymphoma
Mantle Cell Lymphoma
Diffuse Large B-Cell Lymphoma


Follicular Lymphoma

A Phase 2, Multicenter, Open-Label, Randomized Study Comparing INCB050465, a PI3Kδ Inhibitor, to Idelalisib in Relapsed or Refractory Follicular Lymphoma (CITADEL 203)

Treatment agent: INCB050465 (PI3Kδ Inhibitor)
PI: Thomas Stanton, MD
Study Coordinator: Teresa Lund // Teresa.Lund@stjoe.org // (707) 521-3803
Resources and Links: clinicaltrials.gov NCT No: NCT03126019


Marginal Zone Lymphoma

A Phase 2, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects With Relapsed or Refractory Marginal Zone Lymphoma With or Without Prior Exposure to a BTK Inhibitor (CITADEL 204)

Treatment agent: INCB050465 (PI3Kδ Inhibitor)
PI: Thomas Stanton, MD
Study Coordinator: Teresa Lund // Teresa.Lund@stjoe.org // (707) 521-3803
Resources and Links: clinicaltrials.gov NCT No: NCT03144674


Mantle Cell Lymphoma

A Phase 2, Open-Label, Two-Cohort, Multicenter Study of INCB050465, a PI3Kδ Inhibitor, in Relapsed or Refractory Mantle Cell Lymphoma Previously Treated With or Without a BTK Inhibitor (CITADEL 205)

Treatment agent: INCB050465 (PI3Kδ Inhibitor)
PI: Thomas Stanton, MD
Study Coordinator: Teresa Lund // Teresa.Lund@stjoe.org // (707) 521-3803
Resources and Links: clinicaltrials.gov NCT No: NCT03235544


Diffuse Large B-Cell Lymphoma

A Phase 1-2 Dose-Escalation and Cohort-Expansion Study of Oral eFT508 in Subjects with Hematological Malignancies (JIT eFFECTOR)

Treatment agent: eFT508 (MNK1 & MNK2 inhibitor)
PI: Thomas Stanton, MD
Study Coordinator: Kim Young // Kimberly.Young@stjoe.org // (707) 521-3814
Resources and Links: clinicaltrials.gov NCT No: NCT02937675


Multiple Myeloma

A global, prospective, non-interventional, observational study of presentation, treatment patterns, and outcomes in multiple myeloma patients (InsightMM)

Treatment agent: N/A
PI: Ian Anderson, MD
Study Coordinator: Diego Martinez // Diego.Martinez@stjoe.org // (707) 521-3810
Resources and Links: clinicaltrials.gov NCT No: NCT02761187

back to top